INSIDE PHARMA

INSIDE PHARMA

Share this post

INSIDE PHARMA
INSIDE PHARMA
IS DRUG DEVELOPMENT REALLY A RISKY BUSINESS?

IS DRUG DEVELOPMENT REALLY A RISKY BUSINESS?

Yes, but it didn't need to be...

Hedley Rees's avatar
Hedley Rees
Feb 24, 2022
∙ Paid
3

Share this post

INSIDE PHARMA
INSIDE PHARMA
IS DRUG DEVELOPMENT REALLY A RISKY BUSINESS?
Share

FAILURE IS NEVER FAR AWAY IN PHARMA

I’ve lifted a snippet from Find It, File It, Flog It: Pharma's Crippling Addiction and How to Cure it :

“In November 2006, the US Government Accountability Office issued a report titled NEW DRUG DEVELOPMENT: Science, Business, Regulatory, and Intellectual Property Issues Cited as Hampering Drug Development Efforts.

The figure below is a graphic that represents one of the key findings on the risk of failure in drug development.

THE PAINFUL STATISTICS

The statistics speak for themselves. For every 250 compounds that enter the development pipeline, 249 fail to reach their destinations. Is that risky enough for you?”

In a nutshell, the findings were this:

  • 10,000 (patented) molecules screened

  • 250 undergo preclinical development and testing

  • 5 enter clinical development

  • 1 gains approval

  • 249 development candidates fail to make it

  • 4 out of 5 clinical trials fail

  • It takes 10-12 years to gain approval of a development candidate

  • Staggering 90%+ waste,

  • $$$BNs in the bin.

Not…

This post is for paid subscribers

Already a paid subscriber? Sign in
© 2025 Hedley Rees
Privacy ∙ Terms ∙ Collection notice
Start writingGet the app
Substack is the home for great culture

Share